CMN Weekly (14 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 14, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Vor Biopharma
Main focus: Cell therapies for cancer treatment
Company stage: Clinical
Diseases: Acute myeloid leukaemia (AML)
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ:VOR)
Location: Cambridge, MA, USA
Website: https://www.vorbio.com/
Pipeline: https://www.vorbio.com/focus-pipeline/
Partners: Metagenomi
Vor Biosciences is a clinical-stage cell therapy company, with a focus on delivering innovate medicines against cancer, with a primary focus on acute myeloid leukaemia. The company uses its proprietary Vor platform to discover novel targets such as CD123 and CLL-1. The company also uses the platform to discover new targets for non-myeloid malignancies. The company is focused on developing engineered haematopoetic stem cells (eHSC) and CAR-T cells as well as a synergetic treatment using a combination of the two technologies.
Tags
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
